The U.S. House Committee on Oversight and Accountability will hold a hearing on April 11, 2024, tiled “Oversight of the Food and Drug Administration.” The hearing will examine the Oversight Committee’s ongoing investigations into the FDA response to several issues, including the infant formula crisis and food safety, drug shortages, facility inspections, hemp regulation, regulation of tobacco and nicotine products, and over-the-counter decongestants.
“The Oversight Committee has highlighted several crises occurring on the FDA’s watch which have negatively impacted the lives and health of American people and families. From a botched response to a nationwide infant formula crisis, failure to regulate safe tobacco products, failure to prepare for and address critical drug shortages, and more, we have identified how dysfunction at the FDA could be worsening many of these preventable crises. We will hold the Commissioner accountable for what the FDA is doing to address ongoing crises, how they are conducting inspections to prevent nationwide crises in the future, and how they intend to ensure the FDA is first and foremost protecting American consumers,” said Oversight Committee Chairman James Comer (R-Ky.).
The hearing will be livestreamed online on April 11 at 1:00pm ET.
Image: FDA Commissioner Robert Califf, MD
Related Articles
-
Hamburg, one of the longest-serving FDA commissioners in the modern era, told Reuters in an interview that her decision was prompted by the heavy demands of the job and the sheer length of time she has held the position.
-
The cardiologist and former Duke University researcher would be stepping into FDA at an especially busy time.
-
The resignation will be effective in about a month, according to reports.
-
With less than a year under his belt, Robert Califf, M.D. may be leaving the agency.
